SG11201903954WA - Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder - Google Patents
Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorderInfo
- Publication number
- SG11201903954WA SG11201903954WA SG11201903954WA SG11201903954WA SG11201903954WA SG 11201903954W A SG11201903954W A SG 11201903954WA SG 11201903954W A SG11201903954W A SG 11201903954WA SG 11201903954W A SG11201903954W A SG 11201903954WA SG 11201903954W A SG11201903954W A SG 11201903954WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- prophylaxis
- treatment
- blood coagulation
- coagulation disorder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16198497 | 2016-11-11 | ||
| PCT/EP2017/078840 WO2018087271A1 (en) | 2016-11-11 | 2017-11-10 | Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201903954WA true SG11201903954WA (en) | 2019-05-30 |
Family
ID=57389201
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201903954WA SG11201903954WA (en) | 2016-11-11 | 2017-11-10 | Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder |
| SG10201912768YA SG10201912768YA (en) | 2016-11-11 | 2017-11-10 | Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912768YA SG10201912768YA (en) | 2016-11-11 | 2017-11-10 | Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11890327B2 (da) |
| EP (1) | EP3538134B1 (da) |
| JP (1) | JP2020504082A (da) |
| KR (1) | KR20190073576A (da) |
| CN (1) | CN110381986B (da) |
| AU (1) | AU2017358865A1 (da) |
| CA (1) | CA3043397A1 (da) |
| DK (1) | DK3538134T3 (da) |
| ES (1) | ES2908008T3 (da) |
| SG (2) | SG11201903954WA (da) |
| TW (1) | TW201828974A (da) |
| WO (1) | WO2018087271A1 (da) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202010767SA (en) | 2018-05-18 | 2020-11-27 | Bioverativ Therapeutics Inc | Methods of treating hemophilia a |
| CN114072420B (zh) * | 2019-07-04 | 2024-06-11 | 康诺贝林伦瑙有限公司 | 用于增加凝血因子viii的体外稳定性的截短的血管性血友病因子(vwf) |
| JP2023500953A (ja) | 2019-11-11 | 2023-01-11 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | 第ｖｉｉｉ因子に対する寛容を誘導するためのポリペプチド |
| KR102647642B1 (ko) * | 2021-05-04 | 2024-03-15 | (주)케어젠 | 혈액 응고 활성을 갖는 펩타이드와 이의 용도 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| US4970300A (en) | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
| AU6029594A (en) | 1993-01-15 | 1994-08-15 | Enzon, Inc. | Factor viii - polymeric conjugates |
| SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
| IL113010A (en) | 1994-03-31 | 1999-10-28 | Pharmacia & Upjohn Ab | Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration |
| EP1621206A1 (en) | 1994-12-12 | 2006-02-01 | Beth Israel Deaconess Medical Center, Inc. | Chimeric cytokines and uses thereof |
| WO1997003193A1 (en) | 1995-07-11 | 1997-01-30 | Chiron Corporation | Novel factor viii:c polypeptide analogs with altered metal-binding properties |
| SE9503380D0 (sv) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
| AT403764B (de) * | 1996-03-15 | 1998-05-25 | Immuno Ag | Stabiler faktor viii/vwf-komplex |
| ATE319817T1 (de) | 1996-04-24 | 2006-03-15 | Univ Michigan | Gegen inaktivierung resistenter faktor viii |
| US20040092442A1 (en) | 1996-04-24 | 2004-05-13 | University Of Michigan | Inactivation resistant factor VIII |
| AU747391B2 (en) | 1998-04-27 | 2002-05-16 | Cantab Biopharmaceuticals Patents Limited | Pharmaceutical composition comprising factor VIII and neutral liposomes |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6887470B1 (en) | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| JP2005518181A (ja) | 2001-01-12 | 2005-06-23 | ジ・アメリカン・ナショナル・レッド・クロス | 第ｖｉｉｉ因子のヘパラン硫酸プロテオグリカン仲介性クリアランスを低下させるための方法および組成物 |
| WO2002103024A2 (en) | 2001-06-14 | 2002-12-27 | The Scripps Research Institute | Stabilized proteins with engineered disulfide bonds |
| WO2003076567A2 (en) | 2002-03-05 | 2003-09-18 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
| US8586538B2 (en) | 2002-04-29 | 2013-11-19 | Stichting Sanquin Bloedvoorziening | Method of treating a patient suffering from a bleeding disorder comprising administering an antibody against the A3-C1 of FVIII |
| US7041635B2 (en) | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
| CA2788505C (en) | 2003-02-26 | 2018-09-04 | Nektar Therapeutics | Polymer-factor viii moiety conjugates |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| PL2298347T3 (pl) | 2003-05-06 | 2016-03-31 | Bioverativ Therapeutics Inc | Białka chimeryczne czynnika krzepnięcia do leczenia zaburzenia hemostazy |
| CN1802386B (zh) | 2003-06-12 | 2010-12-15 | 伊莱利利公司 | Glp-1类似物融合蛋白质 |
| EP1699821B1 (en) | 2003-12-31 | 2012-06-20 | Merck Patent GmbH | Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS |
| US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| SI3130601T1 (sl) | 2004-11-12 | 2020-11-30 | Bayer Healthcare Llc | Usmerjena modifikacija FVIII |
| WO2006071801A2 (en) | 2004-12-27 | 2006-07-06 | Baxter International Inc | Polymer-von willebrand factor-conjugates |
| JP2008537680A (ja) | 2005-04-14 | 2008-09-25 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 安定性の増大された改変型凝固第ｖｉｉｉ因子およびその誘導体 |
| EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| AU2007245190B2 (en) | 2006-03-31 | 2011-07-21 | Takeda Pharmaceutical Company Limited | Pegylated factor VIII |
| EP3896090B1 (en) | 2006-06-14 | 2022-01-12 | CSL Behring GmbH | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
| KR101542752B1 (ko) | 2006-12-22 | 2015-08-10 | 체에스엘 베링 게엠베하 | 연장된 생체내 반감기를 갖는 변형된 응고 인자 |
| CA2690218C (en) | 2007-06-13 | 2017-02-28 | Csl Behring Gmbh | Use of vwf stabilized fviii preparations and of vwf preparations without fviii for extravascular administration in the therapy and prophylactic treatment of bleeding disorders |
| KR101507718B1 (ko) | 2008-06-24 | 2015-04-10 | 체에스엘 베링 게엠베하 | 연장된 생체내 반감기를 갖는 인자 ｖｉｉｉ, 폰 빌레브란트 인자 또는 이들의 복합체 |
| EP2499165B1 (en) | 2009-11-13 | 2016-09-14 | Grifols Therapeutics Inc. | Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto |
| AU2012340501A1 (en) | 2011-12-19 | 2013-07-11 | Grifols, S.A. | Compositions, methods, and kits for preparing sialylated recombinant proteins |
| PT2804623T (pt) | 2012-01-12 | 2019-11-18 | Bioverativ Therapeutics Inc | Polipéptidos quiméricos do fator viii e suas utilizações |
| WO2013120939A1 (en) | 2012-02-15 | 2013-08-22 | Csl Behring Gmbh | Von willebrand factor variants having improved factor viii binding affinity |
| CN104411716B (zh) * | 2012-04-24 | 2018-09-07 | 诺和诺德股份有限公司 | 适用于治疗血友病的化合物 |
| EP2841091A1 (en) * | 2012-04-24 | 2015-03-04 | Novo Nordisk A/S | Pharmaceutical composition suitable for treatment of haemophilia |
| BR112015000267B1 (pt) | 2012-07-11 | 2023-01-24 | Bioverativ Therapeutics Inc. | Proteínas quiméricas, e composição farmacêutica |
| EP2796145B1 (en) | 2013-04-22 | 2017-11-01 | CSL Ltd. | A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge |
| US20160207977A1 (en) | 2013-06-12 | 2016-07-21 | Novo Nordisk A/S | Compounds Suitable for Treatment of Haemophilia |
| CN106414492B (zh) | 2014-06-06 | 2021-07-06 | 奥克塔法马股份有限公司 | 包含因子viii和冯·维勒布兰德因子肽的制剂 |
| CA2953593C (en) | 2014-07-02 | 2023-09-26 | Csl Limited | Modified von willebrand factor |
| RU2017145002A (ru) | 2015-05-22 | 2019-06-24 | Цсл Беринг Ленгнау Аг | Способы получения модифицированного фактора фон виллебранда |
-
2017
- 2017-11-10 JP JP2019524345A patent/JP2020504082A/ja active Pending
- 2017-11-10 KR KR1020197016644A patent/KR20190073576A/ko not_active Application Discontinuation
- 2017-11-10 AU AU2017358865A patent/AU2017358865A1/en not_active Abandoned
- 2017-11-10 TW TW106139051A patent/TW201828974A/zh unknown
- 2017-11-10 SG SG11201903954WA patent/SG11201903954WA/en unknown
- 2017-11-10 US US16/349,002 patent/US11890327B2/en active Active
- 2017-11-10 CA CA3043397A patent/CA3043397A1/en not_active Abandoned
- 2017-11-10 EP EP17801644.0A patent/EP3538134B1/en active Active
- 2017-11-10 ES ES17801644T patent/ES2908008T3/es active Active
- 2017-11-10 SG SG10201912768YA patent/SG10201912768YA/en unknown
- 2017-11-10 CN CN201780069945.0A patent/CN110381986B/zh active Active
- 2017-11-10 WO PCT/EP2017/078840 patent/WO2018087271A1/en unknown
- 2017-11-10 DK DK17801644.0T patent/DK3538134T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018087271A1 (en) | 2018-05-17 |
| JP2020504082A (ja) | 2020-02-06 |
| US11890327B2 (en) | 2024-02-06 |
| EP3538134B1 (en) | 2021-12-29 |
| CN110381986A (zh) | 2019-10-25 |
| DK3538134T3 (da) | 2022-02-07 |
| AU2017358865A1 (en) | 2019-05-09 |
| EP3538134A1 (en) | 2019-09-18 |
| US20210268071A1 (en) | 2021-09-02 |
| CA3043397A1 (en) | 2018-05-17 |
| SG10201912768YA (en) | 2020-02-27 |
| ES2908008T3 (es) | 2022-04-27 |
| CN110381986B (zh) | 2023-08-18 |
| KR20190073576A (ko) | 2019-06-26 |
| TW201828974A (zh) | 2018-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201903954WA (en) | Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder | |
| SG11201805579SA (en) | Recombinant igg fc multimers | |
| SG11201909572QA (en) | Methods for the treatment of subjects having a hepatitis b virus (hbv) infection | |
| SG11201804294WA (en) | Tank-binding kinase inhibitor compounds | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201900596XA (en) | Cannabis composition | |
| SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
| SG11201907451XA (en) | Substituted imidazo-quinolines as nlrp3 modulators | |
| SG11201806992VA (en) | Antibodies to tigit | |
| SG11201807286WA (en) | Methods and compositions for transducing lymphocytes and regulated expansion thereof | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201804038VA (en) | Conditionally active heterodimeric polypeptides and methods of use thereof | |
| SG11201903950UA (en) | Truncated von willebrand factor polypeptides for treating hemophilia | |
| SG11201805954WA (en) | Methods for modulating intestinal microbiota | |
| SG11201903938XA (en) | Acylated glp-1/glp-2 dual agonists | |
| SG11201408054RA (en) | Pegylated oxm variants | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201809764XA (en) | Humanized anti-il-1r3 antibodies | |
| SG11201901558VA (en) | Pth compounds with low peak-to-trough ratios | |
| SG11201806342SA (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
| SG11201404836QA (en) | Long-acting coagulation factors and methods of producing same | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201901576QA (en) | Dosage regimen for a controlled-release pth compound |